When was Bit.bio founded?

Bit.bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Bit.bio located?

Bit.bio is headquartered in Cambridge, United Kingdom. It is registered at Pioneer House Vision Park, Histon, Cambridge, Cambridgeshire, United Kingdom, CB24 9NL.

Which legal entities is Bit.bio associated with?

Bit.bio is associated with Bit Bio Ltd.

How many employees does Bit.bio have?

As of Aug 31, 2026, the latest employee count at Bit.bio is 132.

Is Bit.bio a funded company?

Bit.bio is a funded company, having raised a total of $266M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 15, 2017.

How much is Bit.bio worth?

The latest valuation of Bit.bio is $***** as of Dec 31, 2021.

When was the latest funding round of Bit.bio?

Bit.bio's latest funding was a $***** Series C round on Jan 09, 2026, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United Kingdom, the Life Sciences Platforms and Tools sector has seen $128M in funding in 2026 to date.

What is the annual revenue of Bit.bio?

Annual revenue of Bit.bio is between £1M and £10M as on Dec 31, 2024

Where does Bit.bio rank among its competitors?

Bit.bio ranks 1st amongst 114 active competitors, of which 30 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Cellply, which secured $8.36M in May, 2026.

Who are the top competitors of Bit.bio?

Bit.bio's top competitors include Cellply, Kiyatec and CytoTronics. Among them, Cellply secured the most recent funding round in May, 2026.

Bit.bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Bit.bio is a series C company based in Cambridge (United Kingdom), founded in 2016 by Mark Kotter. It operates as a Manufacturer of programmed human cells for research and drug discovery. Bit.bio has raised $266M in funding from investors like M&G, Arch Venture Partners and Tencent, with a current valuation of $*****. The company has 114 active competitors, including 30 funded and 15 that have exited. Its top competitors include companies like Cellply, Kiyatec and CytoTronics.

Company Details

Manufacturer of programmed human cells for research and drug discovery. This entity utilizes gene-targeting technology to express transcription factors that reprogram induced pluripotent stem cells into defined human cell types. These products include various nerve, immune, and muscle cell lines designed for use in laboratory assays, disease modeling, and therapeutic development. The technology enables the production of consistent cell models for applications such as CRISPR screening, electrophysiology, and immunocytochemistry.

Website: www.bit.bio/
Social
Email ID: *****@bit.bio
Phone Number: +44 **********
Registered Address: Pioneer House Vision Park, Histon, Cambridge, Cambridgeshire, United Kingdom, CB24 9NL

Key Metrics

Founded Year

2016

Location

Cambridge, United Kingdom

Stage

Series C

Total Funding

$266M in 7 rounds

Latest Funding Round

Series C, Jan 09, 2026, $*****

Post Money Valuation

$***** as on Dec 31, 2021

Investors

M&G & 54 more

Ranked

1^st among 114 active competitors

Annual Revenue

£1M - £10M as on Dec 31, 2024

Employee Count

132 as on Aug 31, 2026

Similar Companies

Cellply & 153 more

View Bit.bio's full profile

Bit.bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bit Bio Ltd CIN: 10466798 , United Kingdom, Active	Nov 06, 2016	£1M - £10M (As on Dec 31, 2024)	219 (As on Dec 31, 2024)

Bit.bio has raised a total funding of $266M over 7 rounds. Its first funding round was on Sep 15, 2017. Its latest funding round was a Series C round on Jan 09, 2026 for $*****. 1 investor participated in its latest round. Bit.bio has 36 institutional investors and 19 angel investors.

Here is the list of recent funding rounds of Bit.bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 09, 2026	7274596	Series C	9650751	1338651	6423827	1928148
Dec 16, 2024	3460568	Series B	1383140	1575520	9657799	Arch Venture Partners & 4 more
Dec 31, 2021	6848095	Series B	6186099	2112182	6096828	5070365

Access funding benchmarks and valuations. Sign up today!

View details of Bit.bio's funding rounds and investors

The founders of Bit.bio is Mark Kotter.

Here are the details of Bit.bio's key team members:

Mark Kotter: Co-Founder of Bit.bio and founder of 2 other companies, Elpis BioMed and Elpis Biomed. They serve on the board of 1 company.
Contact Info: 2 email addresses

Bit.bio's Board of Directors

Bit.bio's board has 6 active members. Mark Kotter and Przemek Obloj are part of team and David Prior, Corneliu Chiriac, Keying Xi and Klevin Lo are independent board members.

Here is the list of Bit.bio's board of directors:

Name	Type	Representing	Status	Duration
Mark Kotter	Team	-	Current	9y 10m
Przemek Obloj	Team	-	Current	1y 7m
David Prior	Independent board member	-	Current	0y 8m
sqnycix	Independent board member	-	Current	4y 6m
jtmldxo	Independent board member	-	Current	7y 9m
z{hnpfe	Independent board member	-	Current	4y 6m

View details of Bit.bio's Founder profiles and Board Members

Bit.bio's employee count trend

Bit.bio has 132 employees as of Aug 26. Here is Bit.bio's employee count trend over the years:

Uncover Bit.bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bit.bio include Cellply, Kiyatec and CytoTronics. Here is the list of Top 10 competitors of Bit.bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	Foresite Capital, Verition Fund Management ... & 53 others	67/100
2nd	Cellply 2013, Bologna (Italy), Series B	Developer of in-vitro diagnostic products for the detection of cancer	$16.4M	LIFTT, Indaco Venture Partners & 15 others	60/100
3rd	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	VentureSouth, MBD Biotech & 13 others	55/100
4th	CytoTronics 2015, Boston (United States), Series A	Developer of cell-based assays for drug discovery	$22.8M	Anzu Partners, BoxOne Ventures & 1 others	55/100
5th	Saguaro 2020, Quebec City (Canada), Seed	Developer of 3D cell culture products for drug discovery	$4.1M	Anges Quebec, AQC Capital & 3 others	50/100
6th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	48/100
7th	Cytotheryx 2018, Rochester (United States), Series A	Developer of human hepatocytes for research and clinical applications	$60M	Ouroboros Family Founders Fund I, QRS Investments ... & 1 others	47/100
8th	StemBioSys 2010, San Antonio (United States), Series A	Cell culture technology company advancing regenerative medicine and drug discovery	$14.5M	JLABS, Targeted Technology & 3 others	45/100
9th	SK Plasma 1970, Seongnam-si (South Korea), Funding Raised	Manufactures plasma derivatives	-	Korea Investment Holdings	45/100
10th	Nanocrine 2018, Frederick (United States), Seed	Provider of a cell analysis and drug design tool for researchers	$300K	TEDCO, America’s Seed Fund	43/100